<DOC>
	<DOCNO>NCT01493115</DOCNO>
	<brief_summary>Primary Objective : To compare pharmacodynamic property two different dos new insulin glargine formulation 0.4 U/kg Lantus® Secondary Objective : To compare pharmacokinetic property two different dos new insulin glargine formulation 0.4 U/kg Lantus® To assess safety tolerability new insulin glargine formulation</brief_summary>
	<brief_title>Single Dose Study With New Insulin Glargine Formulation Lantus® Japanese Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>The study duration per patient 4 12 week include 3 treatment period separate wash-out period 6-20 day</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Japanese male female subject , 20 65 year age , inclusive , type 1 diabetes mellitus one year , define Japanese Diabetes Society Body weight 50.0 kg 95.0 kg Body Mass Index 18.0 30.0 kg/m2 inclusive Stable insulin regimen least 2 month prior study Certified otherwise healthy type 1 diabetes mellitus patient assessment medical history physical examination Women childbearing potential must negative pregnancy test must use highly effective method birth control . During entire study female subject child bear potential must use two independent method contraception . The accepted double contraception method include use intrauterine device hormonal contraception addition one follow contraceptive option : 1 ) condom ; 2 ) diaphragm 3 ) spermicide . Exclusion criterion : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic ( apart diabetes mellitus type 1 ) , hematological , neurological , psychiatric , systemic ( affect body whole ) , ocular , gynecologic ( female ) , infectious disease ; acute infectious disease sign acute illness More one episode severe hypoglycemia seizure , coma require assistance another person past 6 month Presence history drug allergy clinically significant allergic disease accord Investigator 's judgment Participation trial investigational drug past 4 month Symptoms clinically significant illness 3 month study , , accord investigator 's opinion , could interfere purpose study Regular use medication insulin last month study start exception thyroid hormone , lipidlowering antihypertensive drug , , female , exception hormonal contraception menopausal hormone replacement therapy ; vaccination within last 28 day Known hypersensitivity insulin glargine excipients study drug Any history presence deep leg vein thrombosis frequent appearance deep leg vein thrombosis first degree relative ( parent , sibling child ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>